###begin article-title 0
FGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 548 556 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 560 569 560 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
Analyses of Fgf10 and Fgfr2b mutant mice, as well as human studies, suggest that FGF10/FGFR2b signaling may play an essential, nonredundant role during embryonic SMG development. To address this question, we have analyzed the SMG phenotype in Fgf10 and Fgfr2b heterozygous and null mutant mice. In addition, although previous studies suggest that the FGF10/FGFR2b and FGF8/FGFR2c signaling pathways are functionally interrelated, little is known about the functional relationship between these two pathways during SMG development. We have designed in vivo and in vitro experiments to address this question.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 258 267 258 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 512 517 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 510 517 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 517 523 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 523 527 519 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 578 583 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 583 587 579 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 588 594 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 594 597 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 597 603 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 603 606 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 612 618 608 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 620 626 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916; </italic>
###xml 618 626 614 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916; </italic></sup>
###xml 627 633 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 635 640 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 633 640 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 640 646 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 646 649 634 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 857 866 845 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
We analyzed Fgf10 and Fgfr2b heterozygous mutant and null mice and demonstrate dose-dependent SMG phenotypic differences. Hypoplastic SMGs are seen in Fgf10 and Fgfr2b heterozygotes whereas SMG aplasia is seen in Fgf10 and Fgfr2b null embryos. Complementary in vitro studies further indicate that FGF10/FGFR2b signaling regulates SMG epithelial branching and cell proliferation. To delineate the functional relationship between the FGF10/FGFR2b and FGF8/FGFR2c pathways, we compared the SMG phenotype in Fgfr2c+/Delta/Fgf10+/- double heterozygous mice to that seen in wildtype, Fgf10+/- (Fgfr2c+/+/Fgf10+/-) and Fgfr2c+/Delta (Fgfr2c+/Delta/Fgf10+/+) single heterozygous mutant littermates and demonstrate genotype-specific SMG phenotypes. In addition, exogenous FGF8 was able to rescue the abnormal SMG phenotype associated with abrogated FGFR2b signaling in vitro and restore branching to normal levels.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 386 395 386 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 564 572 564 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 636 644 636 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
Our data indicates that FGF10/FGFR2b signaling is essential for the SMG epithelial branching and histodifferentiation, but not earliest initial bud formation. The functional presence of other endogenous signaling pathways could not prevent complete death of embryonic SMG cells in Fgf10 and Fgfr2b null mice. Though we were able to rescue the abnormal phenotype associated with reduced in vitro FGF10/FGFR2b signaling with exogenous FGF8 supplementation, our results indicate that the FGF10/FGFR2b and FGF8/FGFR2c are nonredundant signaling pathways essential for in vivo embryonic SMG development. What remains to be determined is the in vivo functional relationship between the FGF10/FGFR2b signal transduction pathway and other key signaling pathways, and how these pathways are integrated during embryonic SMG development to compose the functional epigenome.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 205 212 205 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PreBud </italic>
###xml 314 326 314 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 674 690 674 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudoglandular </italic>
###xml 782 794 782 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Canalicular </italic>
###xml 798 811 798 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Terminal Bud </italic>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse submandibular gland (SMG) development is initiated with a thickening of the oral epithelium of the mandibular arch around embryonic day 11.5 (E11.5) and is best conceptualized in stages[1,2]. In the PreBud Stage, SMG development begins as thickening of the oral epithelium adjacent to the tongue. During the Initial Bud Stage, this thickening grows down into mandibular arch mesenchyme to form the initial SMG bud. With continued epithelial proliferation and downgrowth, the SMG primordium becomes a solid, elongated epithelial stalk terminating in a bulb. Repeated end-bud branching results in the formation of a network of epithelial branches and terminal buds (the Pseudoglandular Stage). These epithelial branches and terminal buds hollow out by cell apoptosis during the Canalicular and Terminal Bud Stages, respectively, to form the ductal system and presumptive acini, with mucin protein being produced by the presumptive acini.
###end p 9
###begin p 10
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Morphogenesis of complex organs such as the SMG is regulated by the functional integration of parallel and broadly related signaling pathways which regulate cell proliferation, apoptosis and histodifferentiation [3-6]. To understand the complex interactions within this dynamic signaling network, one must first determine the contribution of individual pathways and identify those which play essential, nonredundant roles during embryonic SMG initial bud formation, branching morphogenesis and histodifferentiation.
###end p 10
###begin p 11
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr1</italic>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 545 546 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 547 548 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 549 551 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
The FGF family, with at least 22 members, mediates diverse biological functions such as cell proliferation, branching morphogenesis and histodifferentiation by binding and activating four tyrosine kinase receptors (FGFR 1-4) [see reviews [7-9]]. Tissue-specific alternate splicing of the Fgfr1, Fgfr2 and Fgfr3 genes generates isoforms which differentially bind specific FGF ligands [8,10]. Ligand-receptor binding potentially activates multiple intracellular cascades, including the ERK/RAS/MAPK, P13K, and PLC-gamma/PKC pathways [see reviews [8,9,11]].
###end p 11
###begin p 12
###xml 282 283 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 284 285 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 286 288 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 289 291 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 359 361 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 362 364 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 365 367 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 368 370 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Functional studies have demonstrated that embryonic SMG epithelial cell proliferation, branching morphogenesis, and histodifferentation are regulated through growth factor, cytokine, and transcription factor-mediated signaling pathways, including EGF, TGF-beta, Shh, FGFs, and Eda [2,6,12-21]. Although FGFs have been implicated in embryonic SMG development [13,15,22-24], a more complete understanding of their precise roles will provide insight into the complex network of parallel and broadly-related signaling pathways which regulate SMG organogenesis.
###end p 12
###begin p 13
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 148 152 148 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 477 484 477 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 556 563 556 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 630 637 630 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 659 665 659 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
Gene targeting studies have clearly shown the importance of the FGFR2b (FGFR2-IIIb) signaling pathway for embryonic morphogenesis [22,23,25]. Fgfr2b-/- null mice die at birth due to lung insufficiency and exhibit severe dysmorphic organs, including agenesis or dysplasia of the lungs, mammary glands, pancreas, thyroid, teeth, and limbs [22,23,25,26]. Although FGF1, FGF3, FGF7, and FGF10 bind with high affinity to FGFR2b [8,10], the phenotypic similarities between Fgf10 and Fgfr2b null mice [22-25,27] indicate that FGF10 is the major ligand for FGFR2b in vivo. Of particular interest is the absence of SMGs in E14.5 and older Fgfr2b null mice and newborn Fgf10 null mice [23-25]. However, whether this glandular absence is due to the lack of development of a SMG initial bud (i.e. agenesis) or subsequent aplasia of the initial bud was heretofore unknown.
###end p 13
###begin p 14
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10 </italic>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10 </italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10 </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 440 444 440 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 114 120 <span type="species:ncbi:9606">humans</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
Recently, Entesarian et al. [28] have shown the importance of FGF10 gene dosage for salivary gland development in humans. Individuals with autosomal dominant ALSG (aplasia of lacrimal and salivary gland) exhibit hypoplastic or absent parotid and submandibular glands. ALSG was mapped to 5p13.2-5q13.1 to include the FGF10 gene; heterozygous FGF10 mutations were identified in all family members with ALSG. Complementary study of adult Fgf10+/- mutant mice revealed that Fgf10 heterozygotes have absent parotid glands and smaller SMGs although other organs such as lungs, liver, spleen, pancreas, thyroid, limbs appeared normal.
###end p 14
###begin p 15
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 354 363 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
Taken together, the literature suggests that FGF10/FGFR2b signaling plays an essential, nonredundant, dose-dependent role during embryonic SMG development. To address this postulate, we evaluated SMG development in Fgfr2b and Fgf10 heterozygous mutant and null mice and demonstrate dose-dependent differences in SMG phenotypes. In a complementary set of in vitro experiments, we confirm the importance of FGF10/FGFR2b signaling and demonstrate that enhanced FGF10/FGFR2b signaling significantly induces, and abrogated FGF10/FGFRb signaling significantly diminishes, SMG branching morphogenesis and cell proliferation.
###end p 15
###begin p 16
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 388 393 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 386 393 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 393 399 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 399 403 395 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 446 451 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 451 455 447 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 456 462 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 462 465 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 465 471 461 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 471 474 467 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 480 486 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 488 494 484 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916; </italic>
###xml 486 494 482 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916; </italic></sup>
###xml 495 501 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 503 508 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 501 508 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 508 514 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 514 517 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 712 721 700 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 898 906 886 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
Our previous analyses of mutant mice and functional in vitro studies indicate that the FGF8/FGFR2c signaling pathway is essential for embryonic SMG epithelial branching morphogenesis and histodifferentiation [2,13]. Little is known about the functional relationship between the FGF10/FGFR2b and FGF8/FGFR2c pathways during SMG development. Thus, we evaluated the SMG phenotype in Fgfr2c+/Delta/Fgf10+/- double heterozygous mice, compared them to Fgf10+/- (Fgfr2c+/+/Fgf10+/-) and Fgfr2c+/Delta (Fgfr2c+/Delta/Fgf10+/+) single heterozygous mutant, as well as wildtype (WT), littermates and demonstrate genotype-specific SMG phenotypes. Though we were able to rescue the abnormal phenotype associated with reduced in vitro FGF10/FGFR2b signaling with exogenous FGF8 peptide supplementation, our results indicate that the FGF10/FGFR2b and FGF8/FGFR2c are nonredundant signaling pathways essential for in vivo embryonic SMG development.
###end p 16
###begin title 17
Results
###end title 17
###begin p 18
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 272 284 272 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 456 468 456 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 548 553 548 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A, B</xref>
###xml 690 697 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 751 756 751 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B, C</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 784 790 784 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 790 794 790 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 798 803 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 803 807 803 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 990 995 990 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, D</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1113 1121 1113 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1188 1192 1188 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">not </italic>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 1252 1256 <span type="species:ncbi:10090">mice</span>
To delineate the role of FGF10/FGFR2b signaling during embryonic SMG development, we evaluated the SMG phenotype in Fgf10 and Fgfr2b null and heterozygous mutant mice. The E12.5 normal SMG appears as an elongated solid cord of epithelium terminating in an end-bulb (i.e., Initial Bud Stage) (Fig. 1A). By contrast, the E12.5 Fgfr2b null SMG is severely hypoplastic (compare Fig. 1B to 1A), displaying an extremely small initial bud similar to the earliest Initial Bud Stage [1,2]. A similar phenotype is seen in Fgf10 null mice (compare Fig. 1C to 1A, B). Normally by E13.5, epithelial proliferation results in SMG primordia with end-bulbs characterized by several branches; SMGs from both Fgfr2b and Fgf10 null mice are entirely absent (compare Fig. 2B, C to 2A). On the other hand, Fgfr2b+/- and Fgf10+/- heterozygosity results in SMG branching hypoplasia compared to WT glands, with fewer ducts and terminal buds being seen in heterozygous mutant SMGs than in WT SMG (compare Fig. 3B to 3A, D to 3C). Taken together, our data indicate that FGF10/FGFR2b signaling plays an essential, dose-dependent role during in vivo embryonic SMG branching morphogenesis and histodifferentation, but not earliest initial bud formation. Thus, the pathology in null mice is aplasia, not agenesis.
###end p 18
###begin p 19
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Abnormal SMG phenotypes in E12.5 <italic>Fgfr2b </italic>and <italic>Fgf10 </italic>null mutants A</bold>
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 103 107 103 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 141 145 141 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 182 194 182 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 311 315 311 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 323 327 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 327 331 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 384 396 384 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
Abnormal SMG phenotypes in E12.5 Fgfr2b and Fgf10 null mutants A. E12.5 WT (+/+) mouse. B. E12.5 Fgfr2b-/- (R2b-/-) null mouse. C. E12.5 Fg10-/- null mouse. In the WT mouse (A), the Initial Bud Stage SMG is seen in the mandible ventrolateral to the tongue. By contrast, the SMG bud (outlined in white) in Fgfr2b-/- (B) and Fg10-/- (C) mice is extremely small, resembling the earliest Initial Bud Stage SMG. Bar, 50 mum.
###end p 19
###begin p 20
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SMG aplasia in <italic>Fgfr2b </italic>and <italic>Fgf10 </italic>null mice. </bold>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 77 81 77 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 106 110 106 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 160 177 160 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Late Initial Bud </italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 320 324 320 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 336 340 336 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
###xml 115 120 <span type="species:ncbi:10090">mouse</span>
SMG aplasia in Fgfr2b and Fgf10 null mice. A. E13.5 WT mouse. B. E13.5 Fgfr2b-/- null mouse. C. E13.5 Fg10-/- null mouse. The E13.5 WT SMG (A) has achieved the Late Initial Bud Stage, with several branches being seen in the end-bulb epithelium; a small sublingual gland (SL) bud is seen lateral to the SMG bud. In Fgfr2b-/- (B) and Fg10-/- (C) embryos, no SMGs are found; undifferentiated mesenchyme is seen in the site normally occupied by SMG epithelia. PS-palatal shelf. Bar, 50 mum.
###end p 20
###begin p 21
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hypoplastic SMGs are seen in <italic>Fgfr2b </italic>and <italic>Fgf10 </italic>heterozygous mice. </bold>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 85 89 85 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 111 115 111 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 152 156 152 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 176 180 176 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 207 211 207 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 224 228 224 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 245 263 245 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Late Terminal Bud </italic>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 401 405 401 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fg10</italic>
###xml 417 421 417 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
Hypoplastic SMGs are seen in Fgfr2b and Fgf10 heterozygous mice. A. Newborn WT Fgfr2b+/+ SMG. B. Newborn Fgfr2b+/- heterozygous SMG. C. Newborn WT Fgf10+/+ SMG. D. Newborn Fg10+/- heterozygous SMG. WT Fgfr2b+/+ (A) and Fgf10+/+ (C) mice exhibit Late Terminal Bud Stage SMGs consisting of ducts and terminal buds displaying distinct lumina. In contrast, fewer ducts and terminal buds are seen in Fgfr2b+/- (B) and Fg10+/- (D) heterozygous SMGs compared to WT littermates. Bar, 50 mum.
###end p 21
###begin title 22
###xml 32 41 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Enhanced FGF10/FGFR2b signaling in vitro induces embryonic SMG branching morphogenesis and epithelial cell proliferation
###end title 22
###begin p 23
###xml 247 259 247 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 274 290 274 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudoglandular </italic>
###xml 857 865 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, B, E</xref>
To further delineate the role of FGF10/FGFR2b signaling during embryonic SMG development, we used our well-defined organ culture system to analyze the effect of enhanced FGF10/FGFR2b signaling on embryonic SMG branching morphogenesis. Paired E13 (Initial Bud Stage) or E14 (Pseudoglandular Stage) SMG primordia were cultured for up to 3 days in the presence or absence of FGF10 peptide (200 ng/ml or 500 ng/ml). Since a notable difference in SMG branch number is usually seen among littermates, we compared the number of terminal buds in right and left glands (treated and control) from each embryo. Spooner ratios (end bud number/initial bud number) were determined for each explant, the data were then arcsin transformed, and the mean ratios compared by paired t-test. FGF10 supplementation induced a significant increase in branching morphogenesis (Fig. 4A, B, E): 81% for E13 + 3 [200 ng/ml (P < 0.01); 500 ng/ml (P < 0.001)] and 46% for E14 + 2 [500 ng/ml (P < 0.0001)].
###end p 23
###begin p 24
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enhanced or abrogated FGF10/FGFR2b signaling modulates embryonic SMG branching morphogenesis <italic>in vitro</italic></bold>
Enhanced or abrogated FGF10/FGFR2b signaling modulates embryonic SMG branching morphogenesis in vitro. A-B. Enhanced signaling. Paired E13 SMG primordia were cultured for 3 days in the absence (A) or presence (B) of 500 ng/ml FGF10 peptide supplementation. FGF10 induced a significant increase in branching compared to control (CONT). C-D. Abrogated signaling. Paired E13 SMG primordia were cultured for 3 days in 10 ng/ml IgG-Fc (C) or FGFR2b-Fc chimera (D). FGFR2b-Fc chimera treated explant exhibits a significant decrease in branching compared to IgG-Fc control. Bar, 30 mum. E. Comparison of mean Spooner ratios in E13 + 3 and E14 + 2 explants. Exogenous FGF10 peptide supplementation induced a significant 81% increase in E13 +3 explants [200 ng/ml (P < 0.01); 500 ng/ml (P < 0.001)] and a significant 46% increase in E 14 + 2 explants (P < 0.0001) compared to controls. FGFR2b-Fc chimera-mediated interruption of E13 + 3 and E 14 + 2 SMGs significantly reduced branching morphogenesis by 22% [E13 +3: 10 ng/ml (P < 0.01); E 14 + 2: 5 ng/ml (P > 0.0001); 10 ng/ml (P < 0.01)] compared to controls.
###end p 24
###begin p 25
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 521 522 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 664 670 664 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 632 647 <span type="species:ncbi:10090">transgenic mice</span>
Since cell proliferation is not required for early embryonic SMG epithelial branching [29], we determined if this FGF10-induced increase in branching is due to increased epithelial cell proliferation. We cultured E13+3 SMG primordia in the presence or absence of 500 ng/ml FGF10 peptide and calculated the epithelial cell proliferation index (the number PCNA-positive cells/total number of cells). Exogenous FGF10 induced a significant 78% (P < 0.0001) increase in epithelial cell proliferation compared to control (Fig. 5). Our results are similar to enhanced pancreatic epithelial cell proliferation and pancreatic hyperplasia in transgenic mice with persistent Fgf10 expression in developing pancreatic epithelia [30].
###end p 25
###begin p 26
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enhanced or abrogated FGF10/FGFR2b signaling modulates cell proliferation</bold>
Enhanced or abrogated FGF10/FGFR2b signaling modulates cell proliferation. The cell proliferation index of E13 + 3 explants was calculated as the number of PCNA positive epithelial cells/total epithelial cells. Exogenous FGF10 peptide induced a significant 78% (P < 0.0001) increase, and FGFR2b-Fc chimera resulted in a significant 32% (P < 0.001) decrease, in cell proliferation compared to control.
###end p 26
###begin title 27
###xml 33 42 33 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Abrogated FGF10/FGFR2b signaling in vitro decreases embryonic SMG branching morphogenesis and cell proliferation
###end title 27
###begin p 28
###xml 38 47 38 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 299 308 299 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 363 372 363 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 385 398 385 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo Fgf10</italic>
###xml 398 402 398 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 642 651 642 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 664 678 664 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo Fgf10 </italic>
###xml 1026 1034 1026 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C, D, E</xref>
###xml 1151 1153 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 1180 1188 1180 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
We interrupted FGF10/FGFR2b signaling in vitro by adding exogenous soluble FGFR2b-Fc chimera to the culture medium to competitively bind endogenous FGFR2b ligands. This exogenous receptor/ligand binding methodology has been successfully used to interrupt FGFR2b, FGFR2c, FGFR1b and FGFR1c signaling in vitro [13,15,21]. This experiment was designed to provide an in vitro model of the in vivo Fgf10+/- heterozygous mutant SMG phenotype (i.e. SMG hypoplasia). We conducted dose-response studies and determined the concentration of FGFR2b-Fc chimera which induces a clear biologic effect of reduced branching morphogenesis, thereby creating an in vitro model of the in vivo Fgf10 mutant heterozygote. Paired E13+3 or E14+2 SMG primordia were cultured in IgG-Fc (5 ng/ml or 10 ng/ml) or FGFR2b-Fc chimera (5 ng/ml or 10 ng/ml) and Spooner ratios were determined as described above. E13 + 3 FGFR2b-Fc-treated explants exhibit a significant 22% [10 ng/ml (P < 0.01)] decrease in branching morphogenesis compared to controls (Figs. 4C, D, E); a similar 22% reduction [5 ng/ml (P < 0.001); 10 ng/ml (P < 0.01)] was also seen in E14+2-treated explants (Figs. 4E). These results mimic the in vivo heterozygous mutants reported above.
###end p 28
###begin p 29
###xml 38 47 38 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 436 445 436 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and </italic>
Since exogenous FGF10 supplementation in vitro induced a significant increase in cell proliferation, we then evaluated the epithelial cell proliferation index in E13 +3 SMG primordia with or without abrogated FGF10/FGFR2b signaling. A significant 32% (P < 0.001) decrease in cell proliferation was seen in the presence of 10 ng/ml FGFR2b-Fc chimera compared to control (Fig. 5). Reduction in cell proliferation with FGFR2b-Fc treatment in vitro was also reported by Steinberg et al., [21]. These results indicate that FGF10/FGFR2b signaling modulates embryonic SMG epithelial cell proliferation and branching morphogenesis.
###end p 29
###begin title 30
Relationship between FGFR2b and FGFR2c signaling pathways during SMG development
###end title 30
###begin p 31
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 56 62 56 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916; </italic>
###xml 54 62 54 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916; </italic></sup>
###xml 189 190 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 259 267 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 299 308 295 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 386 388 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 522 524 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 565 572 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 619 624 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 642 644 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 683 688 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 827 835 823 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 927 933 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 937 944 933 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 956 962 952 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 964 969 960 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 962 969 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 969 975 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 975 979 967 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1025 1032 1017 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 1033 1039 1025 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1041 1046 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 1039 1046 1031 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 1046 1052 1034 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1052 1055 1040 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1060 1066 1048 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 1067 1073 1055 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1073 1076 1061 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1076 1082 1064 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1082 1085 1070 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1128 1134 1116 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1134 1137 1122 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1137 1143 1125 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1143 1146 1131 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1174 1179 1162 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B, C</xref>
###xml 1183 1185 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 1201 1207 1189 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1209 1214 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 1207 1214 1195 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 1214 1220 1198 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1220 1224 1204 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1343 1349 1327 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1351 1356 1335 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 1349 1356 1333 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 1356 1362 1336 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1362 1366 1342 1346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1369 1375 1349 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 1375 1378 1355 1358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1378 1384 1358 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 1384 1388 1364 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1416 1418 1396 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 1422 1427 1402 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B, C</xref>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 996 1000 <span type="species:ncbi:10090">mice</span>
Our previous observation of hypoplastic SMGs in Fgfr2c+/Delta deficient mice suggested that FGFR2c signaling is necessary for embryonic SMG branching morphogenesis and histodifferentation [2]. The functional importance of this signaling pathway was confirmed in vitro; reduction of FGFR2c signaling in vitro resulted in a significant dose-dependent decrease in branching morphogenesis [13]. In addition, FGF8, a major FGFR2c ligand, has been shown to play an essential, nonredundant role during embryonic SMG development [13]. Like the hypoplastic SMG phenotype of Fgfr2c deficient mice, hypoplastic glands are seen in Fgf8 hypomorphic mice [13]. Importantly, SMG aplasia is seen in Fgf8 tissue-specific conditional mutant mice. To investigate the relationship between the FGFR2b and FGFR2c signal transduction pathways during in vivo SMG development, we evaluated the SMG phenotype in mice which are heterozygous for both the Fgf10 and Fgfr2c genes (i.e. Fgfr2c+/Delta/Fgf10+/- mutants). Mutant mice heterozygous for either Fgfr2c (Fgfr2c+/Delta/Fgf10+/+) or Fgf10 (Fgfr2c+/+/Fgf10+/-) exhibit hypoplastic SMGs compared to WT (Fgfr2c+/+/Fgf10+/+) littermates (compare Fig. 6B, C to 6A). In contrast, Fgfr2c+/Delta/Fgf10+/- double heterozygous mutant SMGs are smaller and exhibit fewer ducts and terminal buds than seen in single heterozygous Fgfr2c+/Delta/Fgf10+/+ or Fgfr2c+/+/Fgf10+/- mutant glands (compare Fig. 6D to 4B, C). These results suggest that, during embryonic SMG development, the FGFR2b and FGFR2c signal transduction pathways each induce at least some downstream targets that are idiosyncratic and not coincident.
###end p 31
###begin p 32
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 8 13 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 6 13 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 14 19 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 19 23 15 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 0 77 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Fgfr2c</italic><sup>+/<italic>&#916;</italic></sup>/<italic>Fgf10</italic><sup>+/- </sup>double heterozygous mutant SMG is severely hypoplastic</bold>
###xml 90 93 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R2c</italic>
###xml 93 96 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 96 102 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 102 106 98 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 126 128 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2c</italic>
###xml 130 135 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 128 135 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 135 141 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 141 145 133 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 146 152 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 154 159 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 152 159 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 160 165 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 165 168 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 213 216 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R2c</italic>
###xml 216 219 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 220 225 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 225 228 213 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 229 235 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 235 238 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 239 244 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 244 247 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 293 295 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2c</italic>
###xml 297 302 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 295 302 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 302 308 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 308 311 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 312 318 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 320 325 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 318 325 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 325 331 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 331 334 311 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 372 378 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 380 385 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 378 385 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 385 391 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 391 395 367 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 403 409 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 409 412 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 413 419 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Fgf10</italic>
###xml 419 423 395 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 574 580 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 582 587 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 580 587 556 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 587 593 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 593 597 565 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 638 644 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 646 651 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 644 651 616 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 651 657 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 657 661 625 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 669 675 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 675 678 643 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 679 684 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 684 688 652 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
Fgfr2c+/Delta/Fgf10+/- double heterozygous mutant SMG is severely hypoplastic. A. Newborn R2c+/+/Fgf10+/+ WT SMG. B. Newborn R2c+/Delta/Fgf10+/+ (Fgfr2c+/Delta/Fgf10+/+) single heterozygous mutant SMG. C. Newborn R2c+/+/Fgf10+/-(Fgfr2c+/+/Fgf10+/-) single heterozygous mutant SMG. D. Newborn R2c+/Delta/Fgf10+/-(Fgfr2c+/Delta/Fgf10+/-) double heterozygous mutant SMG. The Fgfr2c+/Delta/Fgf10+/+ (B) and Fgfr2c+/+/ Fgf10+/- (C) single heterozygous SMGs have fewer ducts and terminal buds than seen in WT littermates (A). A much smaller, severely hypoplastic gland is seen in Fgfr2c+/Delta/Fgf10+/- double heterozygous mice (D) compared to Fgfr2c+/Delta/Fgf10+/+ (B) and Fgfr2c+/+/Fgf10+/- (C) littermates. Bar, 50 mum.
###end p 32
###begin title 33
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
FGF8 rescues SMGs with interrupted FGF10/FGFR2b in vitro
###end title 33
###begin p 34
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 137 142 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 135 142 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 142 148 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 148 152 144 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 326 334 322 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 473 482 469 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 788 793 784 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A, B</xref>
###xml 1133 1135 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 1357 1359 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
Given that FGF8-mediated signaling plays an essential and unique role during SMG development [13], as well as our observation in Fgfr2c+/Delta/Fgf10+/- double heterozygous mutant mice discussed above, we postulated that exogenous FGF8 peptide would rescue the abnormal SMG phenotype associated with abrogated FGFR2b signaling in vitro. To determine if exogenous FGF8 peptide supplementation could restore branching morphogenesis to normal, we interrupted SMG morphogenesis in vitro with FGFR2b-Fc chimera and attempted to "rescue" these explants and restore branching to the level seen in controls. We cultured paired E13 + 3 SMGs in 10 ng/ml FGFR2b-Fc chimera for an initial period of 3 hours and then in FGFR2b-Fc + 500 ng/ml FGF8 peptide or FGFR2b-Fc alone for a total of 3 days (Fig. 7A, B). A second experiment to confirm that exogenous FGFR2b-Fc chimera decreased SMG branching morphogenesis consisted of paired E13 + 3 cultured in the presence of 10 ng/ml FGFR2b-Fc or IgG-Fc. In this set of experiments, FGFR2b-Fc-treated explants exhibit a significant 20% (P < 0.001) decrease in branching compared to IgG-Fc controls (Fig. 7C). Addition of exogenous FGF8 peptide induced a significant 24% (P < 0.02) increase in branching compared to FGFR2b-Fc treatment alone, thus completely restoring branching morphogenesis to the level seen in controls (Fig. 7C).
###end p 34
###begin p 35
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Exogenous FGF8 supplementation <italic>in vitro </italic>rescues SMG branching morphogenesis. </bold>
Exogenous FGF8 supplementation in vitro rescues SMG branching morphogenesis. Paired E13 embryonic SMGs were preincubated for 3 hrs in 10 ng/ml FGFR2b-Fc chimera and then cultured for a total of 3 days with/without 500 ng/ml FGF8 peptide. A. E13+3 10 ng/ml FGFR2b-Fc-treated explant. B. E13+3 FGFR2b-Fc chimera + FGF8-treated explant. Bar, 30 mum. C. Comparison of Spooner ratios. A significant 20% (P < 0.001) decrease in branching morphogenesis with FGFR2b-Fc chimera abrogation was seen compared to IgG-Fc control. Exogenous FGF8 supplementation induced a significant 24% (P < 0.02) increase in branching to completely restore branching to the level seen in control.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 141 148 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 152 158 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 458 465 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 556 562 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 566 573 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 707 711 707 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 715 720 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 720 724 720 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 839 855 839 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudoglandular </italic>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 498 502 <span type="species:ncbi:10090">mice</span>
The FGF family of growth factors is critical to normal embryogenesis, regulating cell proliferation, survival and apoptosis [8]. Analyses of Fgfr2b and Fgf10 mutant and null mice clearly demonstrate that the FGF10/FGFR2b signal transduction pathway is essential for the development of branching organs, including the lung, mammary gland, lacrimal gland, pancreas, thyroid gland and salivary gland [23-28,31-33]. Although SMGs were absent from E14.5 or older Fgfr2b null mice and newborn Fgf10 null mice [22-25], the presence of an initial SMG bud in E12.5 Fgf10 and Fgfr2b null embryos (Fig. 1) indicates that this is a true aplasia, and not agenesis. Moreover, the absence of SMGs in E13.5 and older Fgfr2b-/- and Fgf10-/- mutants confirms that FGF10/FGFR2b signaling is essential for earliest initial epithelial branching and subsequent Pseudoglandular Stage and older SMG morphogenesis, but not earliest initial bud formation.
###end p 37
###begin p 38
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 424 428 424 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 510 515 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 515 519 515 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 824 830 824 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 834 841 834 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 912 919 912 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 923 929 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
The observed initial SMG bud formation and subsequent aplasia is consistent with the pathogenesis seen in other organs, including the Fgfr2b null mammary gland [26], but differs from that seen in lung and pancreas [24,31,34]. Interestingly, Bellusci and colleagues [26] also detected genotype-specific phenotypic differences in mammary bud formation. A transient single initial mammary gland bud (bud 4) seen in E11.5 Fgfr2b-/- mice is absent in E12.5 mice whereas bud 4 is maintained (but does not branch) in Fgf10-/- mice. This result suggests that FGFR2b signaling is essential to maintain bud 4 and to induce the other mammary placodes whereas another FGFR2b ligand (probably FGF7) acts redundantly with FGF10 to maintain the mammary gland placode. Similarly, differences in pancreatic development were observed between Fgf10 and Fgfr2b null mice [31,35]. Taken together, these results clearly indicate that Fgfr2b and Fgf10 null mice demonstrate tissue-specific differences in affected organs.
###end p 38
###begin p 39
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 14 18 14 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 177 181 177 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10 </italic>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 263 270 263 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 377 381 377 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 390 394 390 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 554 560 554 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 564 571 564 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 789 795 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 795 799 795 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 803 808 803 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 808 812 808 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
Although Fgf10+/- heterozygous mice were described as being normal [24,34], lacrimal, parotid and submandibular gland aplasia or hypoplasia were recently reported in adult Fgf10+/- mice and in ALSG patients with FGF10 heterozygous mutations [28]. To determine if Fgfr2b and Fgf10 gene dosage plays an important role during embryonic SMG development, we evaluated newborn Fgfr2b+/- and Fgf10+/- and found SMG hypoplasia in both (Fig. 3). This is the first report of organ abnormality in Fgfr2b heterozygous mice. Our data indicate that SMG development is Fgf10 and Fgfr2b dose-dependent. Homozygous null mutants exhibit SMG aplasia while heterozygotes exhibit SMG hypoplasia. Moreover, the observations of normal lungs, livers, and limbs [23-25,28,34], but abnormal SMG phenotypes [28], in Fgfr2b+/- and Fgf10+/- mutant mice provides additional evidence of FGF10/FGFR2b tissue-specificity.
###end p 39
###begin title 40
Relationship between FGF10/FGFR2b and FGF8/FGFR2c signaling pathways
###end title 40
###begin p 41
It is critical to remember that FGF10 binding to FGFR2b is part of a much larger genetic network. Organogenesis is the programmed expression of regulatory genes coupled to downstream structural genes and epigenetic events. Specific signaling pathways are parallel and largely functionally redundant; that is, several pathways differentially and combinatorially compensate for the dysfunction of a given individual pathway. There are some pathways, however, that have unique and nonredundant functions. One has always to ask two key questions: Is our pathway of interest functionally redundant or nonredundant? Will a broadly related, not independent, pathway compensate for the dysfunction of our pathway of interest?
###end p 41
###begin p 42
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f10 </italic>
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 308 313 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 313 317 309 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 321 327 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 327 331 323 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 390 395 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 396 400 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8</italic>
###xml 400 401 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 402 403 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 400 403 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic>/<italic>N</italic></sup>
###xml 403 412 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;AP2&#945;</italic>
###xml 412 419 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRESCre</italic>
###xml 412 421 404 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>IRESCre</italic>/+</sup>
###xml 456 461 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 578 580 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 600 605 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 609 616 601 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
The observation of SMG aplasia in Fgf10 and Fgfr2b null mice indicates that the functional presence of other endogenous FGF/FGFR pathways (e.g., FGF8/FGFR2c, FGF/FGFR1) or other signaling pathways (e.g., TGF-alpha/EGF/EGFR, Eda/Edar; IGF-II/IGF-IR) could not prevent complete death of embryonic SMG cells in Fgf10-/- and Fgfr2b-/- mice. Interestingly, although SMG aplasia was also seen in Fgf8 (Fgf8C/N;AP2alphaIRESCre/+) conditional mutant mice in which Fgf8 expression was ablated from first branchial arch epithelium, a small initial SMG bud is still seen in E15.5 embryos [13]. By contrast, the Fgf10and Fgfr2b null SMG bud is much more transient, being seen in E12.5 and absent in E13.5 mice (present study). This suggests that the FGF10/FGFR2b and FGF8/FGFR2c signaling pathways are both essential for branching and that the FGF10/FGFR2b signal is necessary for epithelial bud maintenance at earlier stages than the FGF8/FGFR2c signal.
###end p 42
###begin p 43
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8</italic>
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic>/<italic>N</italic></sup>
###xml 35 45 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">; AP2&#945;</italic>
###xml 45 52 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRESCre</italic>
###xml 45 55 41 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>IRESCre</italic>/+ </sup>
###xml 75 77 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 83 88 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 88 92 84 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 365 370 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 394 400 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 404 411 400 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 717 723 713 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 725 730 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 723 730 719 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 730 736 722 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 736 740 728 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 788 794 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 796 802 788 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916; </italic>
###xml 794 802 786 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916; </italic></sup>
###xml 805 810 793 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 810 814 798 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
The absence of SMGs in both Fgf8C/N; AP2alphaIRESCre/+ conditional mutant [13] and Fgf10-/- null mice (present study) suggests that FGF8 and FGF10 probably induce some of the same downstream targets, although through different receptors (FGF10/FGFR2b and FGF8/FGFR2c). However, the mere fact of ontogenic arrest and SMG aplasia, as well as temporal differences, in Fgf8 conditional mutants and Fgf10 and Fgfr2b null mice indicate that FGF10/FGFR2b and FGF8/FGFR2c signaling pathways induce broadly-related, but unique and nonredundant downstream cascades in SMGs that cannot be compensated by normal function of the other under physiologic conditions. Our observation of smaller and more severely hypoplastic SMGs in Fgfr2c+/Delta/Fgf10+/- double heterozygous mice compared to either the Fgfr2c+/Delta or Fgf10+/- single heterozygous mutants further supports this conclusion.
###end p 43
###begin p 44
###xml 225 226 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 227 228 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 229 231 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 339 348 335 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 349 351 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 352 354 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 355 357 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 420 422 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 460 469 456 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 623 625 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
It is well established that FGF/FGFR signaling can simultaneously activate multiple signaling cascades (e.g., ERK/RAS/MAPK, P13K, and PLC-gamma/PKC to mediate epithelial cell proliferation, survival and histodifferentiation [8,9,11]. Inhibition of ERK/RAS/MAPK or P13K signaling significantly reduced embryonic SMG branching morphogenesis in vitro [17-19,21], whereas inhibition of PKC modestly increased morphogenesis [18]. A recent study of FGFR2b signaling in vitro suggests that FGF10/FGFR2b requires ERK activation to mediate cell proliferation and branching whereas FGF7/FGFR2b requires both ERK and P13K activation [21].
###end p 44
###begin p 45
###xml 97 106 97 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 322 330 322 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 373 382 373 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 542 550 542 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 680 685 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 685 689 685 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 712 716 712 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 730 738 730 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 768 774 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10 </italic>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
Although the importance of ERK/RAS/MAPK, P13K and PKC signaling during embryonic SMG development in vitro has been demonstrated, it is presently unclear which signaling cascades downstream of the FGF10/FGFR2b and FGF8/FGFR2c pathways are essential for epithelial branching morphogenesis, proliferation and survival during in vivo SMG development. This is important because in vitro and in vivo results may not necessarily coincide, suggesting the effect of differing physiologic conditions. Recently, Steinberg et al. [21] demonstrated that, in vitro, once the gland is formed, inhibition of FGF10 does not inhibit branching. This is the precise opposite of that seen in both the Fgf10-/- null mice and the Fgf10+/- heterozygotes in vivo (Fig. 1C, 2C, 3C), as well as FGF10 heterozygous mutant individuals with ALSG syndrome [28].
###end p 45
###begin p 46
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 12 15 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 440 449 440 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 610 619 610 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 925 933 925 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 955 960 955 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 960 964 960 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 968 974 968 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 974 978 974 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1006 1013 1006 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1093 1101 1093 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Fgf10 (Fgf10-/-) or Fgfr2b (Fgfr2b-/-) loss of function is ultimately epistatic to each other and to the epigenome under normal physiologic conditions (i.e. no other gene mutations nor untoward environments), the very reason they are critical to SMG morphogenesis. However, since the epistasis associated with declining Fgf10 or Fgfr2b function is a nonlinear emergent property of the complete functional epigenotype, it can be manipulated in vitro in the manner reported here. Exogenous FGF8 peptide can completely rescue and restore to normal the abnormal phenotype seen with abrogated FGF10/FGFR2 signaling in vitro (Fig. 7). This is not surprising since FGF8 has the ability to simultaneously activate similar, as well as unique and ligand-specific, intracellular cascades which control proliferation, survival, and differentiation. Rescue experiments have always to be only a proof of this principle, not a mimic of the in vivo condition. After all, Fgf10-/- and Fgfr2b-/- mutant SMGs are not rescued in vivo, the very essence of epistatic mutations. What remains to be determined is the in vivo functional relationship between the FGF10/FGFR2b signal transduction pathway and other key downstream signaling pathways, and how these pathways are integrated during embryonic SMG development to compose the functional epigenome.
###end p 46
###begin title 47
Conclusion
###end title 47
###begin p 48
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 315 322 315 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 367 372 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 365 372 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 372 378 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10</italic>
###xml 378 382 374 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 588 596 584 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
Our results indicate that FGF10/FGFR2b signaling is essential for the SMG epithelial branching and histodifferentiation, but not earliest initial bud formation. The functional presence of other endogenous FGF pathways or other signaling pathways could not prevent complete death of embryonic SMG cells in Fgf10 and Fgfr2b null mice. Moreover, our analysis of Fgfr2c+/Delta/Fgf10+/- double heterozygous mice indicates that FGF10/FGFR2b and FGF8/FGFR2c signaling pathways induce broadly-related, but unique and nonredundant downstream cascades in SMGs. What remains to be determined is the in vivo functional relationship between the FGF10/FGFR2b signal transduction pathway and other key downstream signaling pathways, and how these pathways are integrated during embryonic SMG development to compose the functional epigenome.
###end p 48
###begin title 49
Methods
###end title 49
###begin title 50
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Fgf10 and Fgfr2b mutant mice
###end title 50
###begin p 51
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 220 224 220 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10</italic>
###xml 380 383 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b</italic>
###xml 391 395 391 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 143 145 <span type="species:ncbi:10090">WT</span>
###xml 197 199 <span type="species:ncbi:10090">WT</span>
###xml 327 329 <span type="species:ncbi:10090">WT</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 399 401 <span type="species:ncbi:10090">WT</span>
Fgf10 and Fgfr2b mutant mice were generated on a C57Bl/6 background and genotyped by RT-PCR as previously described [23,26,34]. Wildtype mice (WT) (littermates or otherwise) were used as controls. WT (E11.5-E18.5), Fgf10-/- (E11.5-5-E14.5) and Fgfr2b-/- (E11.5-E15.5) embryos were collected. For analysis of heterozygous SMGs, WT and heterozygous mice were mated and newborn Fgf10+/-, Fgfr2b+/- and WT littermates were collected and their genotypes confirmed by RT-PCR. The embryos and newborn heads were fixed in 4% paraformaldehyde in PBS, and stored in 70% ethanol until further processing. E11.5-E14.5 heads and E15 and older SMGs were processed, embedded in paraplast and serial coronal sections were stained with hematoxylin and eosin as previously described [1]. A minimum of 3 SMGs per age per genotype were analyzed.
###end p 51
###begin title 52
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 22 27 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 20 27 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 28 34 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Generation of Fgfr2c+/Delta/Fgf10 +/- mice
###end title 52
###begin p 53
###xml 33 43 33 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2-IIIc</italic>
###xml 45 51 45 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916; </italic>
###xml 43 51 43 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916; </italic></sup>
###xml 169 171 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 217 219 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 245 256 241 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2-IIIc </italic>
###xml 258 263 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 256 263 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 263 271 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;Fgf-10 </italic>
###xml 271 275 263 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 363 369 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 382 388 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 388 391 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 394 396 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 419 430 411 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2-IIIc </italic>
###xml 432 437 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 430 437 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 437 445 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;Fgf-10 </italic>
###xml 445 449 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 459 466 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 468 473 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 466 473 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 473 481 457 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf-10 </italic>
###xml 481 484 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 582 589 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 589 592 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 592 600 576 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/ Fgf10 </italic>
###xml 600 604 584 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 610 617 594 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 617 620 601 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 620 628 604 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/ Fgf10 </italic>
###xml 628 631 612 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 633 640 617 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 642 647 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 640 647 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 647 655 627 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf-10 </italic>
###xml 655 659 635 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 663 670 643 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c </italic>
###xml 672 677 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 670 677 650 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 677 685 653 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf-10 </italic>
###xml 685 689 661 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 690 692 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 935 937 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 938 940 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 605 607 <span type="species:ncbi:10090">WT</span>
###xml 785 787 <span type="species:ncbi:10090">WT</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
Due to their neonatal lethality, Fgfr2-IIIc+/Delta mice are routinely generated by crossing males in which a copy of FgfR2-exon 9 (IIIc) has been flanked by loxP sites [36], with females carrying a PGK-Cre transgene [37]. However, to obtain the Fgfr2-IIIc +/Delta;Fgf-10 +/- allele, we used PGK-Cre females in to which we had previously introduced a heterozygous Fgf10 null allele (Fgf10 +/-) [27]. For simplicity, the Fgfr2-IIIc +/Delta;Fgf-10 +/- is called Fgfr2c +/Delta/Fgf-10 +/-. This cross resulted in the recovery of the following genotypes in the correct Mendelian ratios: Fgfr2c +/+/ Fgf10 +/+ (WT); Fgfr2c +/+/ Fgf10 +/-, Fgfr2c +/Delta/Fgf-10 +/+ and Fgfr2c +/Delta/Fgf-10 +/- [36]. Lines were maintained and crosses were performed in a C57/black 6 background. E17-newborn WT and mutant mice were generated, SMGs were fixed and processed as described above, and their genotypes confirmed by RT-PCR as previously described [27,36]. All animal studies were conducted with the approval of the appropriate committees regulating animal research.
###end p 53
###begin title 54
Culture system
###end title 54
###begin p 55
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 175 187 175 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Initial Bud </italic>
###xml 203 219 203 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudoglandular </italic>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 559 582 559 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Supplementation studies</italic>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1307 1308 1307 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1339 1341 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Timed-pregnant females [C57Bl/10 (B10.A)] were sacrificed on day 13 and day 14 of gestation, and embryos were dissected in cold PBS and staged according to Theiler [38]. E13 (Initial Bud Stage) and E14 (Pseudoglandular Stage) SMG primordia were cultured for up to 3 days using a modified Trowell method as previously described [6]. The medium consisted of BGJb (Life Technologies, Rockville, MD) supplemented with 1% BSA, 0.5 mg ascorbic acid/ml and 50 units penicillin/streptomycin (Life Technologies), pH 7.2, and replicate cultures were changed every day. Supplementation studies: paired E13 and E14 SMG primordia were cultured in the absence or presence of exogenous FGF10 peptide (200 or 500 ng/ml, R and D Systems) for 3 days (E13 + 3) or 2 days (E14 + 2), respectively; controls consisted of enriched BGJb alone. Because a notable difference in SMG epithelial branch number is seen between embryos within a given litter and among litters, we calculated the Spooner branch ratios (end bud number/initial bud number) for each explant as previously described [13] and compared the Spooner branch ratios in right and left glands (treated and control) from each embryo. Mean Spooner ratios were determined, the data were arcsin transformed to insure normality and homoscedasticity, and compared by paired t-test for all embryos studied [39]. In this set of experiments, 4-6 explants per treatment were analyzed.
###end p 55
###begin title 56
Interruption studies
###end title 56
###begin p 57
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 619 633 619 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo Fgf10 </italic>
We interrupted FGF10/FGFR2b signaling using soluble FGFR2b-Fc chimera (R & D Systems, Inc). This method has been successfully used to interrupt FGFR2b, FGFR2c, FGFR1b and FGFR1c signaling during embryonic SMG development [13,15,21]. We conducted dose-response studies in which we cultured paired E13 + 3 or E14 + 2 SMG primordia in the presence of soluble FGFR2b-Fc chimera (5 or10 ng/ml) or control IgG-Fc (5 or 10 ng/ml IgG-Fc; R & D Systems, Inc), analyzed Spooner ratios as described above, and determined the optimal FGFR2b-Fc chimera concentration which results in a hypoplastic gland similar to that seen in the in vivo Fgf10 mutant heterozygotes. In this set of experiments, 4-8 explants per treatment were analyzed. Based on this set of experiments, we used 10 ng/ml FGFR2b-Fc chimera in all subsequent interruption experiments.
###end p 57
###begin title 58
Cell proliferation assay
###end title 58
###begin p 59
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
The cell proliferation index was determined as previously described [6]. Paired E13 + 3 were cultured in 10 ng/ml FGFR2b-Fc or 10 ng/ml IgG-Fc, fixed in 10% formalin, embedded in paraffin and serially-sectioned. The sections were stained with anti-PCNA for 1 hr using the Zymed mouse PCNA kit (South San Francisco, CA) and counterstained with hematoxylin as previously described [13]. The development time was adjusted according to experiment: 2-5 min for supplementation studies and 10-15 min for interruption studies. In these experiments, the cytoplasm appears blue and PCNA-positive cells appear brown. Three explants per group were analyzed. Control and treated explants were serially-sectioned and the midpoint of each explant identified. The section showing the explant's mid-point was selected, as well as the fourth section to the right and the fourth section to the left of the midpoint. This design insured that different buds were counted in each of the 3 sections/treatment. In each section, we photographed terminal bud clusters in the upper left and lower right at 400 x and counted a minimum of 3 buds/area.
###end p 59
###begin p 60
Cell proliferation was quantitated as the ratio of PCNA-positive epithelial cells/total epithelial cells. The mean cell proliferation index was determined per section and the mean cell proliferation index of the three sections/explant was determined for each treatment. The data was arcsin transformed and the means ratios compared by t-test.
###end p 60
###begin title 61
Rescue experiment
###end title 61
###begin p 62
Paired E13 SMG primordia were cultured in 10 ng/ml FGFR2b-Fc chimera for an initial period of 3 hrs and then each pair was cultured in FGFR2b-Fc or FGFR2b-Fc + 500 ng/ml FGF8 (R and D Systems, Inc.) for 3 days. This FGF8 peptide concentration was determined to induce a significant increase in branching morphogenesis (data not shown). A concurrent control experiment was conducted as an internal control to verify that FGFR2b-Fc chimera supplementation interrupted branching morphogenesis; these controls consisted of E13 primordia cultured in 10 ng/ml FGFR2b-Fc chimera or 10 ng/ml IgG-Fc for 3 days. The explants were collected and mean Spooner ratios determined and compared as described above. Four explants per treatment were analyzed.
###end p 62
###begin title 63
List of abbreviations
###end title 63
###begin p 64
ALSG-aplasia of lacrimal and salivary gland
###end p 64
###begin p 65
###xml 4 10 <span type="species:ncbi:9913">bovine</span>
BSA-bovine serum albumen
###end p 65
###begin p 66
CONT-control
###end p 66
###begin p 67
FGF-Fibroblast growth factor
###end p 67
###begin p 68
FGFR2b-FGF receptor 2-IIIb
###end p 68
###begin p 69
FGFR2c-FGF receptor 2-IIIc
###end p 69
###begin p 70
ERK-p44/p42 mitogen activating kinases (ERK-1/2)
###end p 70
###begin p 71
MAPK-mitogen-activating protein kinases
###end p 71
###begin p 72
P13K-phosphatidylinositol 3-kinase
###end p 72
###begin p 73
PBS-phosphate-buffered saline
###end p 73
###begin p 74
PKC-protein kinase C
###end p 74
###begin p 75
PLC-gamma-phospholipase C gamma1
###end p 75
###begin p 76
###xml 3 6 3 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
R2b-/--Fgfr2b-/-
###end p 76
###begin p 77
R2c-Fgfr2c
###end p 77
###begin p 78
RT-PCR-reverse transcriptase-polymerase chain reaction
###end p 78
###begin p 79
SMG-submandibular salivary gland
###end p 79
###begin p 80
###xml 0 2 <span type="species:ncbi:10090">WT</span>
WT-wildtype
###end p 80
###begin title 81
Authors' contributions
###end title 81
###begin p 82
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf10 </italic>
###xml 358 365 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2b </italic>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2c</italic>
###xml 504 509 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 502 509 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>&#916;</italic></sup>
###xml 509 516 505 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Fgf10 </italic>
###xml 516 520 512 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
TJ designed and coordinated the study, was involved in aspects of all experiments, and drafted the manuscript. GA prepared the histological sections for this study and performed some of the morphology and cell proliferation experiments. DW participated in morphological analyses and culture experiments and generated all figures. FGS generated the Fgf10 and Fgfr2b mutant mice and harvested and genotyped the embryos. SB assisted in the analyses of mutant mouse histopathology. MKH generated the Fgfr2c+/Delta/Fgf10 +/- single and double mutant mice, harvested and genotyped these embryos, and assisted in the analysis of their histopatholgy. MM participated in the design and coordination of this study, assisted in the analysis of histopathology, performed the statistical analysis, and helped draft the manuscript. All authors read and approved the final manuscript.
###end p 82
###begin title 83
Acknowledgements
###end title 83
###begin p 84
###xml 88 92 <span type="species:ncbi:10090">mice</span>
We gratefully acknowledge Dr. Clive Dickson in whose laboratory the double heterozygous mice were generated and maintained. This research was supported by a grant from American Lung Association (SB), NIH grants RO1 DE014535 (TJ/MM) and RO1 HL074832 (SB).
###end p 84
###begin article-title 85
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Submandibular gland morphogenesis: stage-specific expression of TGF-alpha, EGF, IGF, TGF-beta, TNF and IL-6 signal transduction in normal mice and the phenotypic effects of TGF-beta2, TGF-beta3, and EGF-R null mutations
###end article-title 85
###begin article-title 86
###xml 166 169 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 178 181 174 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
Embryonic submandibular gland morphogenesis: stage-specific protein localization of FGFs, BMPs, Pax 6 and Pax 9 and abnormal SMG phenotypes in FGF/R2-IIIc+Delta, BMP7-/- and Pax6-/- mice
###end article-title 86
###begin article-title 87
A genomic regulatory network for development
###end article-title 87
###begin article-title 88
Regulatory gene networks and the properties of the development process
###end article-title 88
###begin article-title 89
Inferring genetic networks and identifying compound mode of action via expression profiling
###end article-title 89
###begin article-title 90
The functional genomic response of developing embryonic submandibular glands to NF-kappaB inhibition
###end article-title 90
###begin article-title 91
Signaling by fibroblast growth factors: the inside story
###end article-title 91
###begin article-title 92
Fibroblast growth factors
###end article-title 92
###begin article-title 93
Promotion and attenuation of FGF signaling through the Ras-MAPK pathway
###end article-title 93
###begin article-title 94
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggest distinct pathophysiological mechanisms for craniofacial and limb anomalies.
###end article-title 94
###begin article-title 95
Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors
###end article-title 95
###begin article-title 96
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Gene expression profiles of mouse submandibular gland development: FGFR1 regulates branching morphogenesis in vitro through BMP- and FGF- dependent mechanisms
###end article-title 96
###begin article-title 97
FGF8 dose-dependent regulation of embryonic submandibular salivary gland morphogenesis
###end article-title 97
###begin article-title 98
Sonic Hedgehog signaling plays an essential role during embryonic salivary gland Epithelial Branching Morphogenesis
###end article-title 98
###begin article-title 99
Embryonic salivary gland branching morphogenesis. In Branching Morphogenesis: Davies J. (Ed.)
###end article-title 99
###begin article-title 100
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Epidermal growth factor system is a physiological regulator of development of the mouse fetal submandibular gland and regulates expression of the alpha6-integrin subunit
###end article-title 100
###begin article-title 101
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
The ERK-1/2 signaling pathway is involved in the stimulation of branching morphogenesis of fetal mouse submandibular glands by EGF
###end article-title 101
###begin article-title 102
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
EGF-stimulated signaling by means of P13K, PLCgamma1, and PKC isozymes regulates branching morphogenesis of the fetal mouse submandibular gland
###end article-title 102
###begin article-title 103
Role of PI 3-kinase and PIP3 in submandibular gland branching morphogenesis
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse submandibular gland morphogenesis: a paradigm for embryonic signal processing
###end article-title 104
###begin article-title 105
FGFR2b signaling regulates ex vivo submandibular gland epithelial cell proliferation and branching morphogenesis.
###end article-title 105
###begin article-title 106
Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning.
###end article-title 106
###begin article-title 107
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
An important role for the III isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signaling during mouse organogenesis.
###end article-title 107
###begin article-title 108
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
FGF10 acts as a major ligand for FGF Receptor 2 IIIb in mouse multi-organ development
###end article-title 108
###begin article-title 109
Fibroblast growth factor receptor-2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Msx1, or Bmp4
###end article-title 109
###begin article-title 110
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo
###end article-title 110
###begin article-title 111
###xml 101 111 <span type="species:ncbi:7227">Drosophila</span>
Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless
###end article-title 111
###begin article-title 112
Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands
###end article-title 112
###begin article-title 113
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Cell proliferation is not required for the initiation of early cleft formation in mouse embryonic submandibular epithelium in vitro.
###end article-title 113
###begin article-title 114
Fgf10 maintains Notch activation, stimulates proliferation, and blocks differentiation of pancreatic epithelial cells.
###end article-title 114
###begin article-title 115
Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis
###end article-title 115
###begin article-title 116
Endogenous and Ectopic Gland induction by FGF-10
###end article-title 116
###begin article-title 117
Fgf10 expression identifies parabronchical smooth muscle cell progenitors and is required for their entry into the smooth muscle cell lineage.
###end article-title 117
###begin article-title 118
Fgf10 is essential for limb and lung formation.
###end article-title 118
###begin article-title 119
The IIIb isoform of fibroblast growth factor receptor 2 is required for proper growth and branching of pancreatic ductal epithelium but not for differentiation of exocrine or endocrine cells
###end article-title 119
###begin article-title 120
A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes
###end article-title 120
###begin article-title 121
Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase
###end article-title 121

